Effect of whole pelvic radiotherapy for patients with locally advanced prostate cancer treated with radiotherapy and long-term androgen deprivation therapy

International Journal of Radiation Oncology Biology Physics

Volumn 81, Issue 5, 2011, Pages

  Mantini, Giovanna ^a   Tagliaferri, Luca ^a   Mattiucci, Gian Carlo ^a   Balducci, Mario ^a   Frascino, Vincenzo ^a   Dinapoli, Nicola ^a   Di Ges, Cinzia ^b   Ippolito, Edy ^b   Morganti, Alessio G ^b   Cellini, Numa ^a  

^a FONDAZIONE POLICLINICO UNIVERSITARIO A GEMELLI IRCCS   (Italy)

^b CATHOLIC UNIVERSITY   (Italy)

Author keywords

Long term androgen deprivation therapy; Prophylactic nodal irradiation; Prostate cancer

Indexed keywords

ACUTE TOXICITY; ANDROGEN DEPRIVATION THERAPY; BIOCHEMICAL DISEASE-FREE SURVIVAL (BDFS); GASTROINTESTINAL TOXICITIES; GLEASON SCORES; INFLAMMATORY DISEASE; LOCALLY ADVANCED PROSTATE CANCER; LONG-TERM ANDROGEN DEPRIVATION; PROSTATE CANCER; PROSTATE CANCERS; PROSTATE SPECIFIC ANTIGEN; RANDOMIZED TRIAL; WHOLE PELVIC RADIOTHERAPY;

PATIENT MONITORING; RADIOTHERAPY; TOXICITY;

DISEASES;

PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ANDROGEN DEPRIVATION THERAPY; ARTICLE; BIOCHEMISTRY; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURVIVAL; DISEASE FREE SURVIVAL; FOLLOW UP; GASTROINTESTINAL TOXICITY; GLEASON SCORE; HUMAN; LOCALLY ADVANCED PROSTATE CANCER; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATE ONLY RADIOTHERAPY; RETROSPECTIVE STUDY; RISK ASSESSMENT; TREATMENT DURATION; WHOLE PELVIC RADIOTHERAPY;

ADULT; AGED; AGED, 80 AND OVER; ANDROGEN ANTAGONISTS; DISEASE-FREE SURVIVAL; GASTROINTESTINAL TRACT; HUMANS; LYMPHATIC IRRADIATION; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; NEOPLASM GRADING; NEOPLASM STAGING; PELVIS; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RETROSPECTIVE STUDIES; UROGENITAL SYSTEM;

EID: 81855163385     PISSN: 03603016     EISSN: 1879355X     Source Type: Journal    
DOI: 10.1016/j.ijrobp.2010.12.003     Document Type: Article

References (42)

1. D.G. McGowan The value of extended field radiation therapy in carcinoma of the prostate Int J Radiat Oncol Biol Phys 7 1981 1333 1339 (Pubitemid 12241697)
2. S.S. Ploysongsang, B.S. Aron, and W.M. Shehata Radiation therapy in prostate cancer: Whole pelvis with prostate boost or small field to prostate? Urology 40 1992 18 26
3. S.A. Seaward, V. Weinberg, and P. Lewis Improved freedom from PSA failure with whole pelvic irradiation for high-risk prostate cancer Int J Radiat Oncol Biol Phys 42 1998 1055 1062 (Pubitemid 29004148)
4. S.A. Seaward, V. Weinberg, and P. Lewis Identification of a high-risk clinically localized prostate cancer subgroup receiving maximum benefit from whole-pelvic irradiation Cancer J Sci Am 4 1998 370 377
5. C.C. Pan, K.Y. Kim, and J.M. Taylor Influence of 3D-CRT pelvic irradiation on outcome in prostate cancer treated with external beam radiotherapy Int J Radiat Oncol Biol Phys 53 2002 1139 1145 (Pubitemid 34787848)
6. S.A. Aristizabal, D. Steinbronn, and R.S. Heusinkveld External beam radiotherapy in cancer of the prostate: The University of Arizona experience Radiother Oncol 1 1984 309 315
7. E. Rosen, J.R. Cassady, and J. Connolly Radiotherapy for prostate carcinoma: The JCRT experience (1968-1978). II. Factors related to tumor control and complications Int J Radiat Oncol Biol Phys 11 1985 725 730 (Pubitemid 15086895)
8. G.K. Zagars, A.C. von Eschenbach, and D.E. Johnson Stage C adenocarcinoma of the prostate: An analysis of 551 patients treated with external beam radiation Cancer 60 1987 1489 1499 (Pubitemid 17141000)
9. S.O. Asbell, J.M. Krall, and M.V. Pilepich Elective pelvic irradiation in stage A2.B carcinoma of the prostate: Analysis of RTOG 77-06 Int J Radiat Oncol Biol Phys 15 1988 1307 1316 (Pubitemid 19015471)
10. S.O. Asbell, K.L. Martz, and K.H. Shin Impact of surgical staging in evaluating the radiotherapeutic outcome in RTOG 77-06, a phase III study for T1bN0M0 (A2) and T2N0M0 (B) prostate carcinoma Int J Radiat Oncol Biol Phys 40 1998 769 782 (Pubitemid 28150793)
11. J. Pannek, and A.W. Partin The role of PSA and percent free PSA for staging and prognosis prediction in clinically localized prostate cancer Semin Urol Oncol 16 1998 100 105 (Pubitemid 28394934)
12. A.W. Partin, J. Yoo, and B. Carter The use of prostatic specific antigen, clinical stage and Gleason score to predict pathological stage in men with localized prostate cancer J Urol 150 1993 110 114 (Pubitemid 23175983)
13. A.W. Partin, M.W. Kattan, and E.N. Subong Combination of prostate specific antigen, clinical stage and Gleason score to predict pathological stage in men with localized prostate cancer: A multi-institutional update JAMA 277 1997 1445 1451 (Pubitemid 27208886)
14. A.W. Partin, L.A. Mangold, and D.A. Lamm Contemporary update of prostate cancer staging nomograms (Partin tables) for the new millennium Urology 58 2001 843 848 (Pubitemid 34017254)
15. M. Roach, C. Marquez, and H. You Predicting the risk of lymph node involvement using the pre-treatment prostate specific antigen and Gleason score in men with clinically localized prostate cancer Int J Radiat Oncol Biol Phys 28 1993 33 37 (Pubitemid 24012852)
16. M.V. Pilepich, K. Winter, and C.A. Lawton Androgen suppression adjuvant to definitive radiotherapy in prostate carcinoma - Long-term results of phase III RTOG 85-31 Int J Radiat Oncol Biol Phys 61 1999 1285 1290
17. C.A. Lawton, K. Winter, and D. Grignon Androgen suppression plus radiation versus radiation alone for patients with stage D1/pathologic node-positive adenocarcinoma of the prostate: Updated results based on national prospective randomized trial Radiation Therapy Oncology Group 85-31 J Clin Oncol 23 2005 800 807 (Pubitemid 46224179)
18. M.V. Pilepich, K. Winter, and M.J. John Phase III Radiation Therapy Oncology Group (RTOG) trial 86-10 of androgen deprivation adjuvant to definitive radiotherapy in locally advanced carcinoma of the prostate Int J Radiat Oncol Biol Phys 50 2001 1243 1252 (Pubitemid 32727802)
19. C.A. Lawton, K. Winter, and K. Murray Updated results of the phase III Radiation Therapy Oncology Group (RTOG) trial 85-31 evaluating the potential benefit of androgen suppression following standard radiation therapy for unfavorable prognosis carcinoma of the prostate Int J Radiat Oncol Biol Phys 49 2001 937 946 (Pubitemid 32184600)
20. G.E. Hanks, T.F. Pajak, and A. Porter Phase III trial of long-term adjuvant androgen deprivation after neoadjuvant androgen deprivation cytoreduction and radiotherapy in locally advanced carcinoma of the prostate: The Radiation Therapy Oncology Group protocol 92-02 J Clin Oncol 21 2003 3972 3978 (Pubitemid 46606211)
21. M. Bolla, L. Collette, and L. Blank Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): A phase III randomised trial Lancet 360 2002 103 106
22. M. Roach, C. DeSilvio, and C.A. Lawton Phase III trial comparing whole pelvic versus prostate-only radiotherapy and neoadjuvant versus adjuvant combined androgen suppression: Radiation Therapy Oncology Group 9413 J Clin Oncol 21 2003 1904 1911
23. V. Valentini, F. Maurizi, and L. Tagliaferri SPIDER: Managing clinical data of cancer patients treated through a multidisciplinary approach by a palm based system JPH 5 2008 66 76
24. C. Capirci, C. Polico, and G. Mandoliti Dislocation of small bowel volume within box pelvic treatment fields, using new "up down table" device Int J Radiat Oncol Biol Phys 51 2001 465 473 (Pubitemid 32888172)
25. International Commission on Radiation Units and Measurements ICRU report 50: Prescribing, recording and reporting photon beam therapy 1993 International Commission on Radiation Units and Measurements Bethesda
26. International Commission on Radiation Units and Measurements ICRU report 62: Prescribing, recording and reporting photon beam therapy (supplement to ICRU report 50) 1999 International Commission on Radiation Units and Measurements Bethesda
27. F.L. Greene, D.L. Page, and I.D. Fleming AJCC-UICC cancer staging manual 6th ed 2002 Springer New York
28. M.M. Oken, R.H. Creech, and D.C. Thormey Toxicity and response criteria of the Eastern Cooperative Oncology Group Am J Clin Oncol 5 1982 649 655 (Pubitemid 13149996)
29. J.D. Cox, J. Stetz, and T.F. Pajak Toxicity criteria of the Radiation Therapy Oncology Group (RTOG) and the European Organization for Research and Treatment of Cancer (EORTC) Int J Radiat Oncol Biol Phys 31 1995 1341 1346
30. C.A. Perez, J.M. Michalski, and M.A. Lockett Chemical disease-free survival in localized carcinoma of prostate treated with external beam irradiation: Comparison of American Society of Therapeutic Radiology and Oncology consensus or 1 ng/mL as endpoint Int J Radiat Oncol Biol Phys 49 2001 1287 1296 (Pubitemid 32297595)
31. E.L. Kaplan, and P. Meier Nonparametric estimation from incomplete observations J Am Stat Assoc 53 1958 457 481
32. R. Peto, and J. Peto Asymptomatically efficient rank invariant procedures J R Stat Soc 135 1972 185 207
33. D.R. Cox Regression models and life tables J R Stat Soc B34 1972 187 220
34. N.N. Stone, R.G. Stock, and P. Unger Laparoscopic pelvic lymph node dissection for prostate cancer: Comparison of the extended and modified techniques J Urol 158 1997 1891 1894 (Pubitemid 27433173)
35. A. Heidenreich, Z. Varga, and R. Von Knobloch Extended pelvic lymphadenectomy in patients undergoing radical prostatectomy: High incidence of lymph node metastasis J Urol 167 2002 1681 1686 (Pubitemid 34240702)
36. P. Dirix, K. Haustermans, and S. Junius The role of whole pelvic radiotherapy in locally advanced prostate cancer Radiother Oncol 79 2006 1 14
37. D. Wang, and C. Lawton Pelvic lymph node irradiation for prostate cancer: Who, why, and when? Semin Radiat Oncol 18 2008 35 40 (Pubitemid 350235954)
38. M. Roach III, G. Hanks, and H. Thames Jr. Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: Recommendations of the RTOG-ASTRO Phoenix Consensus Conference Int J Radiat Oncol Biol Phys 65 2006 965 974
39. J.D. Cox, M.J. Gallagher, E.H. Hammond for the American Society for Therapeutic Radiology and Oncology Consensus Panel Consensus statements on radiation therapy for prostate cancer: Guidelines for prostate re-biopsy after radiation and for radiation therapy with rising prostate-specific antigen levels after radical prostatectomy J Clin Oncol 17 1999 1155
40. A.A. Aizer, J.B. Yu, and A.M. McKeon Whole pelvic radiotherapy versus prostate only radiotherapy in the management of locally advanced or aggressive prostate adenocarcinoma Int J Radiat Oncol Biol Phys 75 2009 1344 1349
41. C.A. Perez, H.K. Lee, and A. Georgiou Technical factors affecting morbidity in definitive irradiation for localized carcinoma of the prostate Int J Radiat Oncol Biol Phys 28 1994 811 819 (Pubitemid 24099862)
42. H. Mameghan, R. Fisher, and J. Mameghan Bowel complications after radiotherapy for carcinoma of the prostate: The volume effect Int J Radiat Oncol Biol Phys 18 1990 315 320 (Pubitemid 20097525)